Eribulin
HALAVEN®

About HALAVEN®
-
Marketed by Eisai Inc.
-
Microtubule dynamics inhibitor
-
Treatment of refractory, metastatic breast cancer and liposarcoma
Review and approval status
November 15, 2010
First U.S. approval
March 17, 2011
First E.U. approval
Actual and expected launch:
- 2023: Patent expiry: United States
- 2024: SPC expiry: European Union
- 2024: Patent expiry: Japan
API availability


*Source: Cortellis Generics Intelligence